SCHEMBL3603233

SCHEMBL3603233

Cc1nc2cnc(C(O[SiH2]C(C)(C)C)(c3ccccc3)c3ccccc3)cn2c1C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.41
PRKCB P05771 12/20 0.40
PRKCA P17252 11/20 0.40
PRKCH P24723 11/20 0.40
PRKCE Q02156 11/20 0.40
PRKCQ Q04759 11/20 0.40
PRKCD Q05655 11/20 0.40
CDK2 P24941 4/20 0.40
PRKACA P17612 4/20 0.40
PRKD3 O94806 3/20 0.40
PIM1 P11309 3/20 0.40
PRKACG P22612 3/20 0.40
PRKACB P22694 3/20 0.40
CDK4 P11802 3/20 0.40
CCND1 P24385 3/20 0.40
ABL1 P00519 3/20 0.40
CAMK2D Q13557 3/20 0.40
CCNE2 O96020 2/20 0.40
CCNE1 P24864 2/20 0.40
PRKCG P05129 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599308 0.88 GSK3B (0.42) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3602496 0.79 CAMK2D (0.49) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL10038831 0.78 PRKCA (0.49) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3597774 0.78 PRKCA (0.48) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3603231 0.78 GSK3B (0.43) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL10038835 0.71 PRKCB (0.51) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3613606 0.71 PRKCB (0.54) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3599099 0.70 PRKACA (0.50) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3599304 0.70 GSK3B (0.44) GSK3BPRKCBPRKCAPRKCHPRKCE
SCHEMBL3593072 0.68 ALDH1A1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742132-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2014-06-03 US disclosed
EP-2094689-B1 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-03 EP disclosed
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS NOVARTIS AG 2012-08-30 US disclosed
US-8193236-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2012-06-05 US disclosed
US-20100041693-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2010-02-18 US disclosed
EP-2094689-A2 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2009-09-02 EP disclosed
WO-2008074752-A2 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS RB1, INMT, IDH3A GSK3B 518/4885PRKCB 2976/4885PRKCA 3364/4885
US-20100041693-A1 INDOLYLMALEIMIDE DERIVATIVES IDH3A, IDH2, INMT GSK3B 855/4885PRKCB 3873/4885PRKCA 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.